HerelleX closes its first investment round

HerelleX has closed a first investment round of USD 4.2 million. The money has a concrete, narrow purpose: to take FluoTB from a prototype that works on our test bench to a product that works in a routine laboratory, with the workload and the staffing a routine laboratory actually has.

Who joined

The round was led by a regional health-focused fund, with participation from two strategic investors in the diagnostics sector and from the founding group already on the cap table since the university spin-off.

We chose investors with diagnostics experience rather than software experience for a practical reason: the regulatory path of a medical device looks nothing like that of a digital product, and we needed people at the table who had walked it before.

What the money does

The use of proceeds is split across four fronts, in this order of priority:

• Scaling reporter phage production to end our dependence on imported batches.
• Running the multicentre validation across the four laboratories in the regional network.
• Assembling the regulatory dossier for submission to ANMAT and its Uruguayan counterpart.
• Adding six people to the technical team, focused on quality control and regulatory affairs.

What does not change

The round does not change the focus. We remain a tuberculosis diagnostics company, not a phage platform looking for applications. The temptation to open three new lines because there is now cash is real, and the board's explicit decision was not to, until FluoTB is approved.

Capital buys time and execution capacity. It does not buy scientific certainty: that still comes from bench work.

The next twelve months

The milestone that matters is not financial. It is having the multicentre validation closed, with data that withstands external review, and the regulatory dossier submitted. If that happens, a regional launch enters next year's horizon. If it does not, no funding round makes up for it.